Skip to main content
SMTI logo

Sanara MedTech Inc. (SMTI) Stock Price & Analysis

Sanara MedTech Inc. (SMTI) — MoonshotScore 39/100 (Weak band), calculated Nov 22, 2026. Price $32.55 (-0.37%), as of the Nov 20, 2026 trading session; market cap $299M.

Educational signal · not a buy or sell recommendation · How to read this

$32.55 −$0.12 (-0.37%) Market Cap $299M

Sanara MedTech Inc. · SMTI · NASDAQ

Sanara MedTech Inc. focuses on developing, marketing, and distributing wound and skin care products in the United States. Their product line includes collagen powders and gels, antimicrobial cleansers and gels, and extracellular matrix sheets.

Price as of Nov 20, 2026

Key Statistics

39 of 100

MoonshotScore v2 · Sanara MedTech (SMTI)

Weak
Business Quality Elite (82)
Financial Safety Fragile (18)
Valuation Full (41)
Growth Durability Growing (76)
Momentum Surging (93)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Elite; Financial Safety: Fragile; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 2 of the last 4 reports
  • Altman Z 3.40 · Piotroski F 5
  • ROE -34.9% · ROA 7.0% · current ratio 2.24

Holding back: balance-sheet strain

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SMTI (58 recorded, newest six shown)
RecordedScoreBand
39Weak
38Weak
38Weak
39Weak
39Weak
39Weak

The score was 39 in the stored Nov 21, 2026 snapshot and remains 39 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Momentum +2; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$32.55
Change on the day-0.37%
Market capitalisation$299M
Shares traded on the day51.2K

Price & events

Other perspectives

Council score for Sanara MedTech (SMTI): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Negative
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 22, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Overvalued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as overvalued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Sanara MedTech (SMTI), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Sanara MedTech Inc. (SMTI) is listed on NASDAQ. It employs 108 people. The market values it at $299M.

2 · Latest results

What do the latest results show for Sanara MedTech (SMTI)?

Short answer · as of

Against analyst estimates the company has EPS beat 2 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$26M-$30M-$3.40 (diluted)
Q4 FY2025$28M-$2M-$0.19 (diluted)
Q1 FY2026$28M$458,957$0.05 (diluted)
Q2 FY2026$28M-$452,864-$0.05 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Sanara MedTech (SMTI)?

Short answer · as of

The MoonshotScore pillars rate business quality, durable growth, positive momentum as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z 3.40 · Piotroski F 5. Trailing ratios: ROE -34.9% · ROA 7.0% · current ratio 2.24.

4 · What to check next?

What should you watch next at Sanara MedTech (SMTI)?

Short answer · as of

The stored analyst-target capture is expired, so a current target watchpoint is unavailable.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Sanara MedTech compare with its peers?

Short answer

Sanara MedTech's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Pro-Dex, Inc. (PDEX) Same industry, near in market value$63.00 Nov 20, 2026$202M87 5-pillar Nov 22, 2026
Utah Medical Products, Inc. (UTMD) Same industry, near in market value$69.49 Nov 20, 2026$198M87 5-pillar Nov 22, 2026
InfuSystem Holdings, Inc. (INFU) Same industry, near in market value$14.35 Nov 20, 2026$287M85 5-pillar Nov 22, 2026
STAAR Surgical Company (STAA) Same industry, near in market value$24.22 Nov 20, 2026$1.22B81 5-pillar Nov 22, 2026
Anbio Biotechnology (NNNN) Same industry, near in market value$3.32 Nov 20, 2026$146M55 5-pillar Nov 22, 2026
Jin Medical International Ltd. (ZJYL) Same industry, near in market value$3.38 Nov 20, 2026$538M42 5-pillar Nov 22, 2026
Sanara MedTech (SMTI) — this page$32.55$299M39
AngioDynamics, Inc. (ANGO) Same industry, near in market value$10.81 Nov 20, 2026$455M37 5-pillar Nov 22, 2026
OraSure Technologies, Inc. (OSUR) Same industry, near in market value$3.46 Nov 20, 2026$239M35 5-pillar Nov 22, 2026
DENTSPLY SIRONA Inc. (XRAY) Same industry, near in market value$8.29 Nov 20, 2026$1.65B31 5-pillar Nov 22, 2026
Novocure (NVCR) Same industry, near in market value$10.71 Nov 20, 2026$1.25B26 5-pillar Nov 22, 2026
Kestra Medical Technologies, Ltd. (KMTS) Same industry, near in market value$25.10 Nov 20, 2026$1.50B25 5-pillar Nov 22, 2026
QuidelOrtho Corporation (QDEL) Same industry, near in market value$8.32 Nov 20, 2026$571M24 5-pillar Nov 22, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
$35.00 – $35.00
Last captured analyst target (expired, captured Nov 18, 2026)
$35.00
Last captured median analyst target (expired, captured Nov 18, 2026)
$35.00

Historical target record · Captured · Capture expired; not a current watchpoint.

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 15, 2026

Transactions
9
Identified insiders
9
Purchases
0
Sales
0
Other transactions
9

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SMTI in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SMTI in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Sanara MedTech (SMTI)?

Read these with our analysis →

Sanara MedTech Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the SMTI research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for SMTI?

SMTI carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Sanara MedTech Inc. focuses on developing, marketing, and distributing wound and skin care products in the United States.

Is SMTI a good stock to buy?

Stock Expert AI does not rate SMTI buy, sell or hold. Sanara MedTech Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SMTI stock price today?

The last price recorded for Sanara MedTech Inc. (SMTI), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the SMTI price target?

The last analyst consensus price target we captured for Sanara MedTech Inc. (SMTI), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.

What do analysts say about SMTI stock?

Analyst coverage of Sanara MedTech Inc. (SMTI) is limited, reflecting its small-cap status. Key valuation metrics, such as price-to-sales and price-to-book ratios, may be used to assess its relative valuation compared to peers.

What are the key factors to evaluate for SMTI?

Sanara MedTech Inc. (SMTI) holds a MoonshotScore in the low range. Acquisitions can expand Sanara's product portfolio and market share. Not financial advice.

How frequently does SMTI data refresh on this page?

SMTI's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SMTI's recent stock price performance?

Sanara MedTech Inc. (SMTI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SMTI overvalued or undervalued right now?

Sanara MedTech Inc. (SMTI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 12 from Financial Modeling Prep (FMP), 1 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.